Patents by Inventor Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LINKED DIBENZIMIDAZOLE ANTIVIRALS
    Publication number: 20130295049
    Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: October 30, 2012
    Publication date: November 7, 2013
    Applicant: ENANTA PHARMACEUTICALS, INC
    Inventor: ENANTA PHARMACEUTICALS, INC
  • CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION
    Publication number: 20130183267
    Abstract: The present invention relates to cyclosporin analogues having antiviral activity against HCV and useful in the treatment of HCV infections. More particularly, the invention relates to novel cyclosporin analogue compounds, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
    Type: Application
    Filed: January 4, 2013
    Publication date: July 18, 2013
    Applicant: Enanta Pharmaceuticals, Inc.
    Inventor: Enanta Pharmaceuticals, Inc.
  • 6,11-BRIDGED BIARYL MACROLIDES
    Publication number: 20130165641
    Abstract: The present invention discloses compounds of formula I, II or X, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.
    Type: Application
    Filed: November 26, 2012
    Publication date: June 27, 2013
    Applicant: Enanta Pharmaceuticals, Inc.
    Inventor: Enanta Pharmaceuticals, Inc.
  • QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
    Publication number: 20130144036
    Abstract: The present invention discloses compounds of formula I and II or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: October 22, 2012
    Publication date: June 6, 2013
    Applicant: Enanta Pharmaceuticals, Inc.
    Inventor: Enanta Pharmaceuticals, Inc.